ChEMBL ligand: CHEMBL877 (Acide tranexamique, Acido tranexamico, Amcha, CL 65336, CL-65336, CL65336, Cyclocapron, Cyclo-f, Cyclokapron, Cyklo-f heavy period relief, Cyklokapron, Espercil, Exacyl, Femstrual, Haematrix, LB-1148, LB1148, Lysteda, Menstralite, NSC-291305, Rikavarin, RP-18429, Tranexamic acid, Trans AMCHA, TRANS AMCHA, TRANS-AMCHA, Transamin)
plasminogen/Plasminogen in Human [ChEMBL: CHEMBL1801] [GtoPdb: 2394] [UniProtKB: P00747] There should be some charts here, you may need to enable JavaScript!

DB	Assay description	Assay Type	Standard value	Standard parameter	Original value	Original units	Original parameter	Reference
plasminogen/Plasminogen in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1801] [GtoPdb: 2394] [UniProtKB: P00747]
ChEMBL	Binding affinity to human plasma N-terminal truncated Lys-plasminogen by surface plasmon resonance analysis	B	4.44	pKd	36000	nM	Kd	ACS Med Chem Lett (2014) 5: 538-543 [PMID:24900876]
ChEMBL	Binding affinity to human plasma N-terminal truncated Lys-plasminogen K1 domain by surface plasmon resonance analysis	B	5.66	pKd	2200	nM	Kd	ACS Med Chem Lett (2014) 5: 538-543 [PMID:24900876]
ChEMBL	Binding affinity to human plasma full length Glu-plasminogen K1 domain by surface plasmon resonance analysis	B	5.96	pKd	1100	nM	Kd	ACS Med Chem Lett (2014) 5: 538-543 [PMID:24900876]
ChEMBL	Binding affinity to plasminogen K1 domain (unknown origin)	B	5.96	pKd	1100	nM	Kd	J Med Chem (2020) 63: 1445-1472 [PMID:31658420]
GtoPdb	-	-	3.6	pIC50	241000	nM	IC50	J Thromb Haemost (2007) 5: 2113-8 [PMID:17666018]
ChEMBL	Inhibition of human plasmin assessed as inhibition of fibrinolysis in presence of fibrinogen	B	4.3	pIC50	50000	nM	IC50	Bioorg Med Chem (2016) 24: 545-553 [PMID:26732532]
ChEMBL	Binding affinity to human full length Glu-plasminogen in buffer assessed as inhibition of interaction with fibrin preincubated for 15 mins followed by thrombin addition measured every 2 mins for 15 hrs by Spectra-Max reader analysis in presence of tPA	B	4.92	pIC50	12000	nM	IC50	ACS Med Chem Lett (2014) 5: 538-543 [PMID:24900876]
ChEMBL	Inhibition of human Glu-plasminogen/fibrinogen interaction in HEPES buffer assessed as inhibition of lysis of thrombin-induced clot preincubated for 15 mins prior to thrombin addition measured for 15 hrs by clot-lysis buffer assay	B	4.94	pIC50	11500	nM	IC50	J Med Chem (2013) 56: 3273-3280 [PMID:23521080]
ChEMBL	Inhibition of plasminogen/fibrinogen interaction in pooled citreated human platelet-poor plasma assessed as inhibition of lysis of CaCl2/t-PA-induced clot by microtiter plate analysis	B	5.51	pIC50	3100	nM	IC50	J Med Chem (2013) 56: 3273-3280 [PMID:23521080]
ChEMBL	Binding affinity to full length Glu-plasminogen in human plasma assessed as inhibition of interaction with fibrin in presence of tPA	B	5.51	pIC50	3100	nM	IC50	ACS Med Chem Lett (2014) 5: 538-543 [PMID:24900876]

ChEMBL data shown on this page come from version 34:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]